A Phase 2 interventional study of casirivimab+imdevimab and Moderna mRNA-1273 vaccine in Healthy and Chronic Stable Illness, sponsored by Regeneron Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of the study are:
The secondary objectives of the study are:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine
Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine
Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine
Biological: Moderna mRNA-1273 vaccine
Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine
Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine
Biological: Moderna mRNA-1273 vaccine
Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine
Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine
Biological: Moderna mRNA-1273 vaccine
Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine
Biological: Moderna mRNA-1273 vaccine
Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Also known as: REGN10933, REGN10987, REGN-COV2, REGEN-COV™, Ronapreve™
Single intramuscular (IM) injection
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987 (1200 mg)
High dose - (1200 mg arms)
Time frame: 56 days after first dose of vaccine
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individual Who Received Submaximal Dose Levels of REGN10933+REGN10987 (Less Than 1200 mg)
Submaximal dose - (150 mg, 300 mg, 600 mg, 48 mg, and 12 mg)
Time frame: 56 days after first dose of vaccine
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
Anti-S1-RBD protein
Time frame: Up to 365 Days from 1st dose of Vaccination
Median Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
Anti-S1-RBD protein. Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Time frame: Up to 365 Days from 1st dose of Vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
Anti-S1-RBD protein. Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
Time frame: Up to 365 Days from 1st dose of Vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
\- Anti-S protein (Spike protein)
Time frame: Up to 365 Days from 1st dose of Vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Time frame: Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
Anti-S protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
Time frame: Up to 365 Days from 1st dose of Vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
Anti-S protein
Time frame: Up to 365 Days from 1st dose of vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Time frame: Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
Anti-S protein (Spike) Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
Time frame: Up to 365 Days from 1st dose of vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
Anti-S1-RBD
Time frame: Up to 365 Days from 1st dose of vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Time frame: Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
Anti-S1-RBD protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
Time frame: Up to 365 Days from 1st dose of vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
Anti-S1-RBD
Time frame: Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
Anti-S1-RBD protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
Time frame: Up to 365 Days from 1st dose of vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Time frame: Up to 365 Days from 1st dose of vaccination
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
Anti-S protein (Spike protein)
Time frame: Up to 365 Days from 1st dose of vaccination
Relative Difference Expressed as a Percent in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
Anti-S protein (Spike protein) Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
Time frame: Up to 365 Days from 1st dose of vaccination
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
Anti-S protein (Spike protein) Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
Time frame: Up to 365 Days from 1st dose of vaccination
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to SARS-CoV-2 S Protein Assessed Over Time After the First Dose of Moderna mRNA-1273 Vaccine
Time frame: Up to 365 Days from 1st dose of vaccination
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study
Time frame: Up to 401 Days
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Throughout the Study
Time frame: Up to 401 Days
Number of Participants With Infusion-related Reactions (Grade ≥2) to REGN10933+REGN10987
Time frame: Through Day 4 post-infusion
Number of Participants With Injection Site Reactions (Grade ≥3) to REGN10933+REGN10987
Time frame: Through Day 4 post-infusion
Number of Participants With Injection Site Reactions (Grade ≥3) to Moderna mRNA-1273 Vaccine
Time frame: Through Day 4 post-infusion
Number of Participants With Hypersensitivity Reactions (Grade ≥2) to REGN10933+REGN10987 or Each Dose of Moderna mRNA-1273 Vaccine
Grade 2 - characterized by an adverse local or general response from exposure and oral intervention indicated Grade 3 - hospitalization indicated and intravenous response required Grade 4 - Life Threatening consequence and urgent intervention indicated Grade 5 - Death
Time frame: Through Day 29 post-infusion or post-injection
Concentrations of REGN10933 in Serum Over Time
Time frame: Up to 182 Days
Concentrations of REGN10987 in Serum Over Time
Time frame: Up to 182 Days
Immunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10987
Time frame: Up to Day 183
Immunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10933
Time frame: Up to Day 183
Immunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10987
Time frame: Up to Day 183
Immunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10933
Time frame: Up to Day 183
| Milestone | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Started | 48 | 28 | 29 | 28 | 33 | 31 | 26 | 35 | 35 |
| Completed | 41 | 23 | 24 | 27 | 26 | 24 | 22 | 29 | 32 |
| Not completed | 7 | 5 | 5 | 1 | 7 | 7 | 4 | 6 | 3 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Sponsor request | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 2 | 0 | 2 | 4 | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 | 1 | 5 | 3 | 2 | 2 | 1 |
High dose - (1200 mg arms)
| Titer | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV |
|---|---|---|---|---|
| 50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987 (1200 mg) | 2594.9 ± 1981.5 | 1818.6 ± 2365.8 | 980.8 ± 1015.1 | 2576.8 ± 2736.1 |
Submaximal dose - (150 mg, 300 mg, 600 mg, 48 mg, and 12 mg)
| Titer | Vaccine Only | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|
| 50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individual Who Received Submaximal Dose Levels of REGN10933+REGN10987 (Less Than 1200 mg) | 2594.9 ± 1981.5 | 780.8 ± 771.1 | 716.1 ± 664.9 | 4922.8 ± 11157.3 | 2422.2 ± 2882.7 | 1549.5 ± 4334.1 |
Anti-S1-RBD protein
| Binding Antibody Unit (BAU)/mL | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 18.7 ± 9.2 | 15.7 ± 0.0 | 20.7 ± 25.2 | 15.7 ± 0.0 | 20.1 ± 11.6 | 24.4 ± 22.5 | 22.6 ± 14.4 | 20.2 ± 11.2 | 17.6 ± 10.5 |
| 6 Days after 1st Vaccine | 47.5 ± 31.8 | — | — | — | — | — | 352.9 ± 1590.7 | — | — |
| 14 Days after 1st Vaccine | 1176.5 ± 1758.5 | 884.0 ± 860.0 | 1510.6 ± 2141.5 | 730.4 ± 963.2 | 638.6 ± 662.1 | 673.7 ± 871.0 | 1046.0 ± 1726.3 | 1184.6 ± 1716.7 | 902.0 ± 1485.9 |
| 28 Days after 1st Vaccine | 373.0 ± 416.1 | 276.3 ± 461.4 | 297.8 ± 514.2 | 171.9 ± 193.1 | 209.0 ± 207.0 | 246.0 ± 451.3 | 592.3 ± 1587.1 | 351.0 ± 566.1 | 259.4 ± 520.4 |
| 42 Days after 1st Vaccine | 2610.7 ± 2032.3 | 2318.5 ± 2387.2 | 2190.4 ± 2163.5 | 2022.8 ± 2170.3 | 1989.5 ± 1797.0 | 1246.5 ± 1017.9 | 1460.5 ± 1724.8 | 1714.4 ± 1779.3 | 1763.1 ± 1444.0 |
| 56 Days after 1st Vaccine | 1327.7 ± 1497.7 | 1146.2 ± 1738.7 | 769.1 ± 836.1 | 845.9 ± 1056.3 | 787.9 ± 630.1 | 669.4 ± 813.7 | 841.7 ± 1587.0 | 889.6 ± 1475.2 | 732.0 ± 785.6 |
| 168 Days after 1st Vaccine | 1825.0 ± 2690.3 | 986.3 ± 1718.1 | 358.8 ± 610.3 | 1211.0 ± 2194.5 | 1772.6 ± 2353.2 | 871.1 ± 1584.9 | 3053.1 ± 3077.9 | 715.2 ± 1658.4 | 346.2 ± 888.1 |
| 252 Days after 1st Vaccine | 3665.4 ± 3141.0 | 3488.8 ± 3126.5 | 3180.0 ± 3171.6 | 3174.7 ± 2840.8 | 1508.8 ± 1831.0 | 1539.2 ± 1681.9 | 2898.1 ± 2674.8 | 4269.9 ± 3316.2 | 3556.1 ± 3122.6 |
| 365 Days after 1st Vaccine | 2722.7 ± 2680.0 | 3904.4 ± 3036.1 | 2804.1 ± 2533.8 | 3008.7 ± 2609.0 | 2180.7 ± 1934.9 | 2155.8 ± 2369.2 | 2727.5 ± 2632.9 | 3193.5 ± 2890.2 | 3136.9 ± 2864.3 |
Anti-S1-RBD protein. Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
| Fold Change | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| 6 Days after 1st Vaccine | — | — | — | — | — | 3.2 | — | — |
| 14 Days after 1st Vaccine | 0.8 | 0.6 | 1.6 | 1.1 | 1.9 | 1.3 | 1.0 | 1.3 |
| 28 Days after 1st Vaccine | 1.7 | 2.0 | 2.6 | 1.9 | 2.7 | 1.7 | 1.4 | 2.4 |
| 42 Days after 1st Vaccine | 1.5 | 1.6 | 1.7 | 1.9 | 1.9 | 2.3 | 2.1 | 1.4 |
| 56 Days after 1st Vaccine | 1.5 | 2.0 | 1.8 | 1.7 | 2.4 | 3.0 | 2.0 | 2.3 |
| 168 Days after 1st Vaccine | 1.8 | 4.3 | 1.8 | 1.0 | 1.1 | 0.2 | 2.9 | 3.6 |
| 252 Days after 1st Vaccine | 1.0 | 1.4 | 1.3 | 4.2 | 3.2 | 1.3 | 0.7 | 1.0 |
| 365 Days after 1st Vaccine | 0.4 | 0.9 | 0.9 | 0.9 | 1.2 | 1.0 | 0.7 | 0.9 |
Anti-S1-RBD protein. Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
| Percent | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | -9.8 (-24.4 to 7.5) | -2.3 (-18.1 to 16.6) | -10.1 (-24.7 to 7.2) | 5.0 (-11.6 to 24.8) | 13.7 (-5.1 to 36.2) | 13.3 (-5.7 to 36.1) | 6.0 (-10.2 to 25.2) | -4.7 (-19.3 to 12.6) |
| 6 Days after 1st Vaccine | — | — | — | — | — | -28.7 (-80.7 to 163.6) | — | — |
| 14 Days after 1st Vaccine | -15.3 (-54.4 to 57.1) | -6.2 (-49.9 to 75.5) | -43.6 (-69.9 to 5.5) | -31.6 (-62.6 to 25.2) | -33.9 (-64.9 to 24.7) | -35.0 (-65.5 to 22.7) | 5.2 (-41.5 to 89.2) | -3.2 (-46.1 to 73.7) |
| 28 Days after 1st Vaccine | -37.3 (-65.1 to 12.6) | -48.6 (-71.4 to -7.7) | -52.3 (-73.5 to -14.3) | -43.6 (-68.2 to -0.1) | -51.6 (-73.5 to -11.8) | -32.5 (-63.0 to 23.2) | -24.0 (-56.2 to 31.8) | -50.9 (-71.8 to -14.5) |
| 42 Days after 1st Vaccine | -28.3 (-55.9 to 16.6) | -28.3 (-55.7 to 16.0) | -29.8 (-56.6 to 13.4) | -22.3 (-51.4 to 24.3) | -53.3 (-72.1 to -21.9) | -54.6 (-73.1 to -23.5) | -39.4 (-61.4 to -4.7) | -32.6 (-57.4 to 6.7) |
| 56 Days after 1st Vaccine | -31.6 (-59.9 to 16.9) | -44.7 (-67.2 to -6.7) | -41.8 (-65.5 to -1.9) | -28.9 (-57.4 to 18.5) | -59.9 (-76.9 to -30.5) | -55.1 (-74.1 to -22.2) | -41.9 (-64.5 to -5.1) | -40.9 (-64.1 to -2.6) |
| 168 Days after 1st Vaccine | -49.8 (-76.6 to 7.6) | -71.8 (-86.7 to -4.0) | -47.8 (-75.2 to 9.9) | 7.1 (-49.6 to 127.2) | -41.2 (-73.1 to 28.9) | 66.1 (-25.0 to 267.7) | -59.3 (-79.9 to -17.5) | -72.7 (-86.6 to -44.5) |
| 252 Days after 1st Vaccine | -23.2 (-68.9 to 89.3) | -49.4 (-79.5 to 25.2) | -16.9 (-65.6 to 100.5) | -59.9 (-84.2 to 1.7) | -58.1 (-84.4 to 12.6) | -23.4 (-70.5 to 99.2) | 6.9 (-55.3 to 155.8) | -26.2 (-68.6 to 73.0) |
| 365 Days after 1st Vaccine | 78.4 (-10.0 to 253.7) | 0.6 (-48.8 to 97.9) | 39.0 (-27.4 to 166.2) | 3.0 (-47.6 to 102.5) | -19.7 (-61.3 to 66.6) | 19.5 (-40.9 to 141.7) | 30.4 (-31.5 to 148.3) | 31.6 (-29.8 to 146.9) |
\- Anti-S protein (Spike protein)
| Binding Antibody Unit (BAU)/mL | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 11.7 ± 10.8 | 12.8 ± 15.7 | 8.5 ± 7.3 | 11.6 ± 14.7 | 14.2 ± 21.7 | 14.7 ± 26.1 | 17.3 ± 39.7 | 7.7 ± 3.8 | 12.9 ± 18.6 |
| 6 Days after 1st Vaccine | 27.1 ± 29.2 | — | — | — | — | — | 662.5 ± 3155.1 | — | — |
| 14 Days after 1st Vaccine | 1597.4 ± 2367.2 | 1319.8 ± 1020.4 | 1984.7 ± 2708.3 | 1003.7 ± 1102.0 | 1020.7 ± 879.1 | 970.4 ± 1165.0 | 1636.9 ± 3070.8 | 1742.4 ± 2871.0 | 1494.4 ± 2303.0 |
| 28 Days after 1st Vaccine | 522.1 ± 466.7 | 400.1 ± 534.2 | 337.5 ± 386.9 | 246.6 ± 207.4 | 321.4 ± 309.2 | 343.1 ± 490.0 | 581.7 ± 1292.8 | 434.5 ± 425.0 | 349.0 ± 518.6 |
| 42 Days after 1st Vaccine | 3147.1 ± 2905.2 | 2868.6 ± 2645.0 | 2472.4 ± 2243.8 | 2765.6 ± 3830.7 | 2396.0 ± 1923.4 | 1892.7 ± 1462.3 | 2089.8 ± 2548.4 | 2080.7 ± 1477.7 | 2029.1 ± 1652.4 |
| 56 Days after 1st Vaccine | 1393.0 ± 1232.5 | 1218.0 ± 1192.6 | 941.5 ± 817.6 | 858.8 ± 849.3 | 1013.9 ± 818.1 | 813.1 ± 753.4 | 872.3 ± 1076.6 | 1009.6 ± 1182.4 | 911.9 ± 889.7 |
| 168 Days after 1st Vaccine | 2060.3 ± 3446.9 | 931.9 ± 1466.0 | 405.6 ± 568.3 | 1378.0 ± 3168.9 | 1966.2 ± 3280.9 | 1251.0 ± 3206.3 | 2982.3 ± 3720.5 | 702.1 ± 1502.8 | 354.8 ± 591.3 |
| 252 Days after 1st Vaccine | 4666.6 ± 5091.4 | 3753.9 ± 3919.0 | 3940.5 ± 5162.1 | 3497.8 ± 3891.3 | 1341.3 ± 1963.8 | 1911.1 ± 3022.5 | 2867.2 ± 3284.6 | 5957.8 ± 5727.3 | 5012.0 ± 5693.1 |
| 365 Days after 1st Vaccine | 2808.8 ± 2971.8 | 3549.5 ± 2982.6 | 2703.2 ± 2444.5 | 2903.6 ± 3225.5 | 2302.4 ± 3101.0 | 3204.6 ± 4670.9 | 2944.1 ± 3850.8 | 3717.2 ± 4290.7 | 3648.0 ± 4074.5 |
Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
| Fold Change | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 6 Days after 1st Vaccine | — | — | — | — | — | 0.7 | — | — |
| 14 Days after 1st Vaccine | 0.8 | 0.7 | 1.5 | 1.0 | 1.8 | 0.8 | 0.8 | 1.3 |
| 28 Days after 1st Vaccine | 1.9 | 1.9 | 2.6 | 2.0 | 2.7 | 2.1 | 1.4 | 2.8 |
| 42 Days after 1st Vaccine | 1.4 | 1.6 | 1.7 | 1.6 | 1.5 | 1.5 | 1.7 | 1.9 |
| 56 Days after 1st Vaccine | 1.5 | 1.9 | 1.9 | 1.5 | 2.0 | 2.2 | 1.7 | 2.1 |
| 168 Days after 1st Vaccine | 1.5 | 2.2 | 1.6 | 0.9 | 1.1 | 0.2 | 1.6 | 2.6 |
| 252 Days after 1st Vaccine | 0.9 | 1.1 | 1.3 | 3.1 | 3.8 | 1.2 | 0.6 | 0.9 |
| 365 Days after 1st Vaccine | 0.6 | 1.0 | 1.0 | 1.0 | 1.1 | 1.3 | 0.8 | 1.0 |
Anti-S protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
| Percent | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 0.8 (-26.7 to 38.5) | -20.2 (-42.0 to 9.8) | -8.8 (-33.6 to 25.4) | 3.0 (-24.6 to 40.6) | -3.2 (-30.2 to 34.1) | 2.2 (-26.6 to 42.3) | -23.1 (-43.0 to 3.7) | -5.6 (-30.1 to 27.6) |
| 6 Days after 1st Vaccine | — | — | — | — | — | -2.3 (-80.9 to 398.9) | — | — |
| 14 Days after 1st Vaccine | -3.7 (-43.7 to 64.7) | 1.8 (-40.9 to 75.5) | -34.7 (-62.1 to 12.5) | -22.9 (-54.4 to 30.4) | -27.4 (-58.2 to 25.9) | -21.6 (-54.8 to 36.1) | 10.4 (-33.7 to 83.8) | 8.8 (-34.6 to 80.7) |
| 28 Days after 1st Vaccine | -36.8 (-62.2 to 5.9) | -50.5 (-70.5 to -17.1) | -53.6 (-72.3 to -22.2) | -44.2 (-66.3 to -7.6) | -51.8 (-71.6 to -18.2) | -40.4 (-64.9 to 1.2) | -23.9 (-53.1 to 23.7) | -48.7 (-68.5 to -16.4) |
| 42 Days after 1st Vaccine | -18.5 (-47.2 to 25.9) | -24.0 (-50.6 to 16.7) | -25.3 (-51.3 to 14.8) | -16.5 (-45.1 to 26.9) | -39.4 (-61.7 to -4.1) | -39.8 (-62.3 to -4.1) | -29.9 (-53.2 to 5.0) | -36.7 (-58.0 to -4.5) |
| 56 Days after 1st Vaccine | -21.5 (-50.8 to 25.5) | -35.0 (-58.9 to 2.7) | -42.7 (-63.7 to -9.4) | -22.8 (-50.6 to 20.8) | -54.5 (-71.9 to -26.3) | -47.5 (-67.6 to -15.0) | -33.5 (-56.7 to 2.3) | -39.9 (-61.1 to -6.9) |
| 168 Days after 1st Vaccine | -41.5 (-70.7 to 16.9) | -66.8 (-83.3 to -34.2) | -46.7 (-72.9 to 4.7) | 11.4 (-43.8 to 120.6) | -36.9 (-69.1 to 28.6) | 63.2 (-20.7 to 235.9) | -56.8 (-77.2 to -17.8) | -70.1 (-84.3 to -42.9) |
| 252 Days after 1st Vaccine | -23.9 (-68.2 to 82.1) | -47.5 (-78.1 to 25.8) | -23.6 (-67.4 to 79.1) | -63.8 (-85.3 to -11.0) | -58.4 (-84.0 to 8.4) | -29.9 (-72.1 to 76.5) | 18.1 (-49.2 to 174.4) | -23.9 (-66.6 to 73.5) |
| 365 Days after 1st Vaccine | 44.4 (-23.5 to 172.5) | 4.4 (-44.3 to 95.5) | 11.3 (-39.1 to 103.4) | -7.6 (-50.6 to 72.9) | -17.6 (-58.2 to 62.3) | -0.0 (-48.0 to 92.2) | 13.2 (-37.7 to 105.8) | 26.0 (-29.7 to 126.0) |
Anti-S protein
| Binding Antibody Unit (BAU)/mL | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 4.5 ± 3.9 | 8.1 ± 10.4 | 4.4 ± 2.7 | 3.2 ± 1.2 | 5.9 ± 6.7 | 59.8 ± 267.1 | 5.1 ± 5.4 | 3.0 ± 1.4 | 4.0 ± 3.3 |
| 6 Days after 1st Vaccine | 4.0 ± 1.8 | — | — | — | — | — | 624.8 ± 3025.9 | — | — |
| 14 Days after 1st Vaccine | 409.7 ± 527.4 | 600.2 ± 1399.6 | 205.9 ± 175.8 | 256.3 ± 298.9 | 1742.9 ± 5319.5 | 497.1 ± 1620.0 | 1059.4 ± 3414.4 | 211.8 ± 226.6 | 345.1 ± 679.0 |
| 28 Days after 1st Vaccine | 676.8 ± 878.5 | 468.6 ± 860.3 | 173.3 ± 137.1 | 183.7 ± 168.5 | 1450.6 ± 4361.4 | 366.7 ± 1040.5 | 973.5 ± 3309.8 | 318.2 ± 390.6 | 598.7 ± 2096.6 |
| 42 Days after 1st Vaccine | 4900.0 ± 3970.8 | 3814.3 ± 3083.2 | 2769.7 ± 2535.4 | 2816.7 ± 2858.9 | 5074.9 ± 6044.3 | 2179.8 ± 928.5 | 3968.7 ± 3806.8 | 2797.7 ± 1787.2 | 2852.9 ± 2450.6 |
| 56 Days after 1st Vaccine | 3459.1 ± 3498.4 | 3737.3 ± 4638.6 | 1841.8 ± 1012.7 | 1849.9 ± 1693.2 | 3432.9 ± 5246.8 | 2227.5 ± 2300.0 | 3358.0 ± 4515.3 | 1980.6 ± 1470.2 | 2361.7 ± 2513.4 |
| 168 Days after 1st Vaccine | 2208.7 ± 3093.8 | 2156.7 ± 4354.7 | 900.0 ± 2018.7 | 1862.8 ± 3723.4 | 2973.3 ± 4045.5 | 1346.4 ± 1762.0 | 4609.3 ± 5678.3 | 940.1 ± 1486.8 | 729.5 ± 889.1 |
| 252 Days after 1st Vaccine | 6319.0 ± 6625.5 | 5682.5 ± 6074.3 | 4138.0 ± 5343.0 | 7004.3 ± 7077.5 | 4784.2 ± 4832.5 | 4974.1 ± 6150.0 | 6830.1 ± 5394.9 | 6806.3 ± 7138.7 | 6855.6 ± 7833.3 |
| 365 Days after 1st Vaccine | 5724.1 ± 4944.5 | 8865.1 ± 7110.6 | 7888.9 ± 7014.8 | 7596.9 ± 7438.6 | 4954.4 ± 5226.5 | 5263.3 ± 6235.8 | 3819.3 ± 3262.7 | 9836.6 ± 7299.8 | 10863.1 ± 7822.4 |
Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
| Fold Change | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 0.4 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 6 Days after 1st Vaccine | — | — | — | — | — | 0.5 | — | — |
| 14 Days after 1st Vaccine | 1.6 | 1.7 | 1.8 | 3.5 | 2.5 | 1.0 | 2.4 | 2.1 |
| 28 Days after 1st Vaccine | 3.1 | 4.1 | 3.7 | 2.8 | 3.7 | 2.6 | 2.3 | 2.9 |
| 42 Days after 1st Vaccine | 1.1 | 1.5 | 1.6 | 1.1 | 1.4 | 1.2 | 1.3 | 1.4 |
| 56 Days after 1st Vaccine | 1.2 | 1.5 | 1.8 | 1.1 | 1.4 | 1.6 | 1.6 | 1.6 |
| 168 Days after 1st Vaccine | 1.7 | 1.7 | 1.8 | 0.4 | 1.1 | 0.4 | 1.3 | 1.5 |
| 252 Days after 1st Vaccine | 1.1 | 1.4 | 0.6 | 1.2 | 1.2 | 0.5 | 1.0 | 1.2 |
| 365 Days after 1st Vaccine | 0.7 | 0.7 | 0.9 | 1.6 | 1.8 | 1.4 | 0.5 | 0.5 |
Anti-S protein (Spike) Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
| Percent | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 58.9 (15.4 to 118.9) | 3.0 (-25.3 to 41.9) | -18.7 (-41.0 to 12.0) | 18.3 (-13.5 to 61.9) | 29.4 (-6.9 to 79.8) | 5.4 (-24.5 to 47.1) | -22.9 (-43.0 to 4.2) | -10.3 (-33.8 to 21.5) |
| 6 Days after 1st Vaccine | — | — | — | — | — | 88.0 (-65.3 to 919.3) | — | — |
| 14 Days after 1st Vaccine | -25.1 (-60.2 to 41.0) | -48.5 (-72.9 to -2.1) | -44.5 (-70.8 to 5.4) | -29.9 (-62.2 to 30.2) | -47.8 (-72.8 to -0.2) | 8.2 (-43.5 to 107.0) | -34.0 (-63.8 to 20.3) | -28.3 (-60.6 to 30.4) |
| 28 Days after 1st Vaccine | -45.5 (-70.6 to 1.0) | -64.1 (-80.6 to -33.4) | -63.4 (-80.3 to -32.1) | -33.8 (-63.8 to 21.0) | -57.0 (-77.2 to -19.1) | -28.4 (-62.0 to 34.9) | -38.6 (-65.6 to 9.8) | -45.7 (-69.7 to -2.6) |
| 42 Days after 1st Vaccine | -25.5 (-52.2 to 16.3) | -50.1 (-67.9 to -22.6) | -45.9 (-65.1 to -16.0) | -15.3 (-44.9 to 30.2) | -46.7 (-66.7 to -14.7) | -46.4 (-66.8 to -13.5) | -35.4 (-57.3 to -2.3) | -34.7 (-57.1 to -0.6) |
| 56 Days after 1st Vaccine | 6.2 (-33.3 to 69.1) | -34.8 (-58.6 to 2.8) | -36.6 (-59.7 to -0.1) | -6.9 (-40.3 to 45.1) | -23.6 (-52.7 to 23.3) | -18.9 (-49.8 to 30.9) | -29.1 (-53.8 to 8.7) | -20.9 (-48.8 to 22.1) |
| 168 Days after 1st Vaccine | -29.1 (-61.4 to 30.1) | -54.2 (-74.9 to -16.5) | -29.5 (-61.0 to 27.5) | 48.6 (-18.4 to 170.8) | -9.3 (-51.5 to 69.4) | 98.9 (5.6 to 274.8) | -40.6 (-66.2 to 4.3) | -48.0 (-70.5 to -8.3) |
| 252 Days after 1st Vaccine | -13.4 (-61.3 to 93.9) | -47.4 (-76.6 to 17.9) | 4.4 (-52.4 to 129.3) | -2.6 (-57.6 to 123.5) | -5.2 (-60.8 to 129.3) | 49.1 (-36.4 to 249.7) | 28.2 (-41.2 to 179.4) | -12.2 (-59.0 to 87.9) |
| 365 Days after 1st Vaccine | 65.6 (-10.0 to 204.6) | 44.0 (-21.1 to 163.0) | 38.1 (-22.6 to 146.4) | -3.1 (-46.9 to 76.9) | -20.2 (-58.3 to 53.0) | -23.9 (-59.4 to 42.4) | 78.7 (0.7 to 217.0) | 116.6 (23.7 to 279.3) |
Anti-S1-RBD
| Binding Antibody Unit (BAU)/mL | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 6.6 ± 4.0 | 14.0 ± 21.4 | 6.8 ± 2.8 | 5.6 ± 3.0 | 9.0 ± 6.0 | 111.4 ± 512.7 | 9.2 ± 8.7 | 5.4 ± 2.4 | 7.5 ± 10.3 |
| 6 Days after 1st Vaccine | 7.2 ± 2.8 | — | — | — | — | — | 940.8 ± 4569.2 | — | — |
| 14 Days after 1st Vaccine | 403.4 ± 650.2 | 521.4 ± 1411.9 | 185.9 ± 262.0 | 153.1 ± 218.2 | 2830.5 ± 9711.1 | 493.7 ± 1936.3 | 1340.3 ± 5510.0 | 159.7 ± 165.2 | 290.9 ± 729.9 |
| 28 Days after 1st Vaccine | 809.4 ± 1100.8 | 448.4 ± 841.7 | 206.0 ± 177.2 | 182.3 ± 214.1 | 2050.2 ± 6594.9 | 418.5 ± 1282.0 | 1417.6 ± 5411.7 | 353.5 ± 434.6 | 597.0 ± 2153.3 |
| 42 Days after 1st Vaccine | 7638.6 ± 7214.2 | 7336.3 ± 6920.7 | 4969.6 ± 4706.1 | 4776.7 ± 5241.9 | 10764.3 ± 17718.4 | 3229.9 ± 1467.4 | 5665.7 ± 5297.2 | 4342.8 ± 3047.2 | 4537.6 ± 4153.6 |
| 56 Days after 1st Vaccine | 5595.6 ± 6439.6 | 6945.4 ± 10762.4 | 3123.9 ± 1915.7 | 3148.8 ± 3404.7 | 7023.8 ± 14395.7 | 4077.9 ± 4581.2 | 4864.7 ± 6282.4 | 3080.5 ± 2507.4 | 3775.4 ± 3840.3 |
| 168 Days after 1st Vaccine | 4007.7 ± 6218.6 | 4208.6 ± 9593.8 | 1578.5 ± 3810.3 | 3438.9 ± 7459.7 | 5873.1 ± 9336.1 | 2243.6 ± 3035.3 | 10359.9 ± 14463.6 | 1372.4 ± 2310.7 | 1262.8 ± 1957.9 |
| 252 Days after 1st Vaccine | 13505.1 ± 15811.0 | 13428.1 ± 15027.8 | 9549.2 ± 14673.8 | 1487.0 ± 18618.2 | 9124.4 ± 11583.7 | 11189.1 ± 16641.6 | 12902.6 ± 10578.8 | 14503.6 ± 19241.8 | 17456.8 ± 23681.5 |
| 365 Days after 1st Vaccine | 11268.3 ± 11087.5 | 21517.0 ± 23659.3 | 16569.7 ± 15884.0 | 16959.2 ± 20989.3 | 10225.9 ± 13257.7 | 11261.7 ± 15375.7 | 6301.3 ± 5284.8 | 19774.5 ± 16462.8 | 23135.5 ± 19481.4 |
Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
| Fold Change | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 0.4 | 0.7 | 1.0 | 0.5 | 1.0 | 1.0 | 1.0 | 1.0 |
| 6 Days after 1st Vaccine | — | — | — | — | — | 1.0 | — | — |
| 14 Days after 1st Vaccine | 2.1 | 2.3 | 3.4 | 3.5 | 3.0 | 1.3 | 2.3 | 2.6 |
| 28 Days after 1st Vaccine | 2.8 | 3.5 | 4.2 | 2.6 | 4.0 | 2.2 | 2.2 | 2.7 |
| 42 Days after 1st Vaccine | 1.1 | 1.3 | 1.5 | 1.0 | 1.4 | 1.3 | 1.3 | 1.2 |
| 56 Days after 1st Vaccine | 1.1 | 1.3 | 1.8 | 1.2 | 1.3 | 1.5 | 1.5 | 1.6 |
| 168 Days after 1st Vaccine | 1.8 | 1.6 | 1.5 | 0.4 | 0.9 | 0.3 | 1.3 | 1.5 |
| 252 Days after 1st Vaccine | 0.9 | 1.9 | 0.9 | 1.5 | 1.8 | 0.7 | 1.1 | 1.5 |
| 365 Days after 1st Vaccine | 0.7 | 0.6 | 0.8 | 1.4 | 1.6 | 1.4 | 0.5 | 0.4 |
Anti-S1-RBD protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
| Percent | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 58.3 (13.8 to 120.2) | 7.3 (-22.9 to 49.4) | -13.0 (-37.5 to 21.1) | 27.5 (-7.7 to 76.1) | 25.8 (-10.4 to 76.5) | 18.2 (-16.2 to 66.7) | -14.3 (-37.2 to 17.0) | -9.0 (-33.4 to 24.4) |
| 6 Days after 1st Vaccine | — | — | — | — | — | 43.3 (-72.8 to 654.8) | — | — |
| 14 Days after 1st Vaccine | -35.5 (-67.0 to 26.1) | -53.3 (-76.3 to -7.7) | -59.9 (-79.7 to -20.9) | -38.5 (-68.1 to 18.4) | -56.2 (-78.0 to -12.9) | -16.4 (-58.0 to 66.5) | -44.1 (-70.4 to 5.6) | -39.1 (-67.7 to 14.8) |
| 28 Days after 1st Vaccine | -50.8 (-74.3 to -6.0) | -66.0 (-82.2 to -34.8) | -71.3 (-85.0 to -45.0) | -43.2 (-69.8 to 7.1) | -60.6 (-79.7 to -23.4) | -40.7 (-69.5 to 15.2) | -46.4 (-70.9 to -1.5) | -52.0 (-74.0 to -11.5) |
| 42 Days after 1st Vaccine | -11.8 (-45.9 to 43.7) | -41.2 (-63.7 to -4.6) | -40.7 (-63.4 to -3.8) | -0.0 (-37.6 to 60.3) | -44.0 (-66.6 to -6.1) | -46.4 (-68.3 to -9.4) | -30.3 (-55.8 to 9.8) | -27.5 (-54.3 to 15.1) |
| 56 Days after 1st Vaccine | 14.8 (-29.8 to 87.5) | -29.3 (-56.2 to 14.2) | -34.5 (-59.4 to 5.8) | -0.3 (-37.6 to 59.2) | -10.8 (-46.2 to 47.8) | -19.1 (-51.2 to 34.1) | -28.3 (-54.4 to 12.5) | -14.2 (-45.7 to 35.6) |
| 168 Days after 1st Vaccine | -26.0 (-62.0 to 44.1) | -50.5 (-74.4 to -4.3) | -20.4 (-58.4 to 52.6) | 60.7 (-16.8 to 210.5) | -3.1 (-51.2 to 92.5) | 135.3 (17.4 to 371.6) | -45.2 (-70.4 to 1.8) | -45.2 (-70.6 to 2.1) |
| 252 Days after 1st Vaccine | -3.9 (-61.0 to 136.6) | -48.3 (-79.1 to 27.6) | 10.5 (-54.2 to 166.3) | -6.6 (-63.1 to 136.6) | -1.4 (-63.3 to 164.8) | 48.4 (-42.8 to 285.2) | 19.1 (-50.2 to 184.7) | 1.8 (-56.5 to 138.4) |
| 365 Days after 1st Vaccine | 102.8 (4.5 to 293.4) | 63.5 (-15.1 to 214.7) | 45.5 (-22.5 to 173.1) | 2.7 (-46.6 to 97.5) | -14.9 (-58.1 to 72.6) | -27.8 (-63.5 to 42.8) | 82.8 (-2.0 to 241.1) | 145.7 (33.6 to 351.9) |
Anti-S1-RBD
| Binding Antibody Unit (BAU)/mL | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 7.0 ± 7.3 | 7.1 ± 5.2 | 7.5 ± 7.7 | 6.4 ± 4.1 | 6.5 ± 6.8 | 6.9 ± 4.2 | 7.0 ± 4.9 | 6.1 ± 3.2 | 5.7 ± 2.6 |
| 6 Days after 1st Vaccine | 8.9 ± 6.8 | — | — | — | — | — | 13.1 ± 20.9 | — | — |
| 14 Days after 1st Vaccine | 53.8 ± 70.8 | 29.2 ± 38.7 | 25.5 ± 26.2 | 35.1 ± 64.5 | 852.6 ± 4399.3 | 14.3 ± 13.9 | 42.3 ± 47.9 | 774.5 ± 4180.7 | 34.4 ± 81.2 |
| 28 Days after 1st Vaccine | 34.5 ± 32.4 | 17.3 ± 22.3 | 14.8 ± 16.0 | 17.5 ± 25.1 | 848.9 ± 4400.0 | 14.2 ± 16.1 | 27.3 ± 28.1 | 750.8 ± 4114.9 | 17.9 ± 39.7 |
| 42 Days after 1st Vaccine | 55.5 ± 57.2 | 38.5 ± 55.9 | 20.3 ± 16.8 | 21.7 ± 18.3 | 869.2 ± 4396.1 | 37.9 ± 33.7 | 40.5 ± 38.4 | 762.2 ± 4113.0 | 29.0 ± 35.5 |
| 56 Days after 1st Vaccine | 34.1 ± 34.9 | 20.6 ± 29.4 | 11.8 ± 9.7 | 12.2 ± 9.3 | 37.0 ± 79.2 | 19.8 ± 16.7 | 27.1 ± 23.3 | 30.9 ± 63.0 | 17.6 ± 19.9 |
| 168 Days after 1st Vaccine | 11.7 ± 9.5 | 8.9 ± 6.1 | 8.7 ± 10.6 | 10.8 ± 14.4 | 15.8 ± 22.1 | 9.4 ± 10.9 | 12.1 ± 9.2 | 9.1 ± 11.4 | 6.5 ± 4.4 |
| 252 Days after 1st Vaccine | 13.6 ± 13.3 | 10.2 ± 6.9 | 11.1 ± 12.7 | 10.5 ± 9.1 | 17.9 ± 36.1 | 10.2 ± 12.6 | 12.8 ± 18.5 | 875.0 ± 4481.7 | 16.9 ± 22.8 |
| 365 Days after 1st Vaccine | 9.2 ± 6.5 | 8.6 ± 5.6 | 8.1 ± 6.4 | 9.6 ± 9.7 | 13.7 ± 18.3 | 7.2 ± 5.7 | 14.6 ± 22.8 | 10.6 ± 15.7 | 11.8 ± 13.5 |
Anti-S1-RBD protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
| Percent | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 5.9 (-15.9 to 33.5) | 3.5 (-17.9 to 30.5) | -1.5 (-21.8 to 24.2) | -4.7 (-24.1 to 19.5) | 6.0 (-16.4 to 34.5) | 3.6 (-18.6 to 31.8) | -1.7 (-20.9 to 22.3) | -4.9 (-23.6 to 18.4) |
| 14 Days after 1st Vaccine | -43.7 (-69.0 to 2.3) | -50.9 (-73.2 to -10.0) | -54.7 (-75.3 to -16.9) | -36.7 (-64.7 to 13.7) | -62.8 (-79.9 to -31.3) | -10.9 (-51.7 to 64.7) | -34.9 (-63.1 to 14.8) | -41.0 (-66.5 to 3.8) |
| 28 Days after 1st Vaccine | -46.6 (-70.0 to -5.1) | -53.6 (-73.9 to -17.3) | -53.3 (-73.8 to -17.0) | -26.5 (-58.2 to 29.0) | -52.0 (-73. to -13.4) | -15.5 (-53.2 to 52.5) | -27.7 (-57.9 to 24.3) | -51.3 (-71.7 to -16.0) |
| 42 Days after 1st Vaccine | -22.7 (-56.1 to 36.4) | -55.9 (-74.8 to -22.7) | -51.5 (-72.3 to -15.1) | 8.0 (-37.6 to 86.8) | -18.2 (-55.1 to 49.2) | -20.2 (-56.6 to 46.9) | -36.3 (-62.4 to 8.0) | -43.0 (-66.7 to -2.5) |
| 56 Days after 1st Vaccine | -33.6 (-58.8 to 7.2) | -58.2 (-73.8 to -33.2) | -56.6 (-72.8 to -30.8) | -16.8 (-47.3 to 31.3) | -32.9 (-59.0 to 9.8) | -14.0 (-47.5 to 40.6) | -37.7 (-59.8 to -3.2) | -42.3 (-63.1 to -9.8) |
| 168 Days after 1st Vaccine | -18.5 (-42.5 to 15.5) | -30.5 (-50.8 to -1.8) | -17.8 (-41.5 to 15.6) | 6.8 (-24.3 to 50.8) | -23.8 (-46.8 to 9.1) | 3.2 (-28.3 to 48.5) | -27.3 (-47.4 to 0.5) | -35.4 (-53.4 to -10.5) |
| 252 Days after 1st Vaccine | -15.2 (-48.4 to 39.1) | -20.0 (-51.3 to 31.6) | -19.3 (-50.3 to 30.9) | -17.2 (-50.3 to 38.1) | -22.3 (-54.9 to 33.8) | -13.0 (-48.5 to 46.9) | 20.6 (-25.3 to 94.8) | 6.4 (-33.4 to 69.9) |
| 365 Days after 1st Vaccine | -4.0 (-34.7 to 41.1) | -12.4 (-40.2 to 28.1) | -6.6 (-35.2 to 34.7) | 8.3 (-26.0 to 58.4) | -19.1 (-46.4 to 22.1) | 13.5 (-23.7 to 68.8) | -8.7 (-36.5 to 31.2) | 8.1 (-24.1 to 54.1) |
Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
| Fold Change | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 14 Days after 1st Vaccine | 1.9 | 1.8 | 2.6 | 2.4 | 3.3 | 1.0 | 2.1 | 2.3 |
| 28 Days after 1st Vaccine | 2.3 | 3.1 | 5.0 | 2.1 | 5.0 | 1.4 | 2.3 | 5.0 |
| 42 Days after 1st Vaccine | 2.0 | 2.4 | 2.8 | 1.6 | 1.9 | 1.5 | 3.1 | 2.3 |
| 56 Days after 1st Vaccine | 1.5 | 2.8 | 2.8 | 1.1 | 1.4 | 0.9 | 1.7 | 1.6 |
| 168 Days after 1st Vaccine | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 0.9 | 2.1 | 2.1 |
| 252 Days after 1st Vaccine | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 1.0 |
| 365 Days after 1st Vaccine | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
Anti-S protein (Spike protein)
| Binding Antibody Unit (BAU)/mL | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 5.1 ± 5.6 | 5.7 ± 6.6 | 7.1 ± 9.6 | 5.7 ± 6.3 | 3.9 ± 2.9 | 4.8 ± 3.5 | 4.3 ± 2.9 | 3.7 ± 2.0 | 4.3 ± 3.7 |
| 6 Days after 1st Vaccine | 5.0 ± 2.6 | — | — | — | — | — | 10.0 ± 21.3 | — | — |
| 14 Days after 1st Vaccine | 82.1 ± 84.1 | 50.1 ± 61.0 | 32.2 ± 33.4 | 53.8 ± 99.1 | 579.5 ± 2919.4 | 21.4 ± 21.8 | 57.9 ± 56.6 | 535.1 ± 2773.1 | 53.8 ± 133.3 |
| 28 Days after 1st Vaccine | 52.6 ± 48.3 | 24.3 ± 37.2 | 18.7 ± 28.8 | 23.0 ± 37.6 | 56.0 ± 187.7 | 41.4 ± 136.9 | 34.3 ± 34.7 | 55.1 ± 151.0 | 23.4 ± 52.6 |
| 42 Days after 1st Vaccine | 86.3 ± 90.0 | 57.2 ± 90.2 | 31.1 ± 29.5 | 30.4 ± 26.3 | 604.2 ± 2914.7 | 66.2 ± 85.5 | 61.4 ± 57.3 | 65.5 ± 111.5 | 42.8 ± 47.5 |
| 56 Days after 1st Vaccine | 50.3 ± 58.4 | 28.1 ± 44.0 | 17.8 ± 20.9 | 14.2 ± 10.6 | 47.7 ± 96.6 | 32.3 ± 39.8 | 42.2 ± 43.1 | 40.3 ± 74.5 | 25.9 ± 29.1 |
| 168 Days after 1st Vaccine | 10.4 ± 9.6 | 7.0 ± 6.4 | 8.8 ± 12.4 | 9.7 ± 14.0 | 16.6 ± 21.9 | 11.5 ± 13.4 | 12.1 ± 8.5 | 7.0 ± 10.6 | 5.9 ± 4.8 |
| 252 Days after 1st Vaccine | 13.1 ± 13.9 | 9.6 ± 6.9 | 10.2 ± 11.0 | 9.3 ± 6.8 | 19.9 ± 45.7 | 11.7 ± 13.4 | 14.1 ± 18.5 | 38.4 ± 147.4 | 15.7 ± 19.1 |
| 365 Days after 1st Vaccine | 8.8 ± 7.6 | 8.9 ± 6.4 | 9.5 ± 9.9 | 8.3 ± 6.9 | 13.0 ± 20.4 | 8.0 ± 6.6 | 13.1 ± 18.6 | 9.3 ± 10.0 | 12.5 ± 13.1 |
Anti-S protein (Spike protein) Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%
| Percent | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 8.9 (-16.7 to 42.4) | 14.7 (-12.4 to 50.1) | 6.3 (-18.7 to 39.1) | -12.1 (-32.4 to 14.3) | 3.9 (-21.1 to 36.9) | -7.3 (-29.9 to 22.6) | -13.3 (-32.7 to 11.6) | -5.8 (-26.9 to 21.5) |
| 14 Days after 1st Vaccine | -42.1 (-69.6 to 10.2) | -58.9 (-78.6 to -21.0) | -60.1 (-79.2 to -23.3) | -54.7 (-75.9 to -15.0) | -66.8 (-82.8 to -35.6) | -21.8 (-59.6 to 51.5) | -40.2 (-67.5 to 10.3) | -44.7 (-69.9 to 1.8) |
| 28 Days after 1st Vaccine | -56.7 (-76.4 to -20.4) | -69.2 (-83.3 to -43.4) | -64.6 (-80.7 to -35.0) | -50.2 (-72.5 to -9.8) | -61.6 (-79.4 to -28.4) | -31.7 (-63.4 to 27.4) | -52.7 (-73.3 to -16.3) | -58.7 (-76.8 to -26.7) |
| 42 Days after 1st Vaccine | -32.5 (-60.5 to 15.2) | -63.0 (-78.2 to -37.1) | -56.9 (-74.6 to -26.8) | -7.5 (-44.8 to 55.2) | -19.2 (-54.1 to 42.4) | -21.1 (-55.6 to 40.1) | -46.7 (-67.6 to -12.3) | -43.7 (-66.1 to -6.7) |
| 56 Days after 1st Vaccine | -37.3 (-63.3 to 6.9) | -61.7 (-77.3 to -35.5) | -62.8 (-77.9 to -37.3) | -20.3 (-52.1 to 32.7) | -34.4 (-62.1 to 13.7) | -14.4 (-50.6 to 48.2) | -45.1 (-66.4 to -10.3) | -39.3 (-63.1 to -0.1) |
| 168 Days after 1st Vaccine | -29.0 (-53.6 to 8.8) | -33.0 (-56.1 to 2.1) | -19.5 (-46.9 to 22.0) | 9.4 (-28.2 to 66.7) | -14.8 (-45.0 to 32.2) | 17.4 (-24.8 to 83.2) | -37.2 (-57.7 to -6.7) | -35.9 (-57.0 to -4.6) |
| 252 Days after 1st Vaccine | -19.7 (-51.3 to 32.5) | -31.0 (-58.2 to 14.0) | -21.1 (-51.6 to 28.7) | -22.1 (-53.5 to 30.5) | -17.5 (-52.4 to 42.9) | -3.1 (-43.0 to 64.6) | -4.5 (-41.2 to 55.0) | -2.6 (-39.3 to 56.3) |
| 365 Days after 1st Vaccine | 4.0 (-33.6 to 62.7) | -1.3 (-36.6 to 53.7) | -5.7 (-38.4 to 44.3) | 1.2 (-35.0 to 57.5) | -9.5 (-43.9 to 46.0) | 5.6 (-33.4 to 67.5) | -3.0 (-36.4 to 47.8) | 27.1 (-15.8 to 91.9) |
Anti-S protein (Spike protein) Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)
| Fold Change | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Baseline | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 6 Days after 1st Vaccine | — | — | — | — | — | 1.0 | — | — |
| 14 Days after 1st Vaccine | 2.1 | 2.4 | 2.8 | 3.2 | 2.9 | 1.1 | 3.0 | 2.0 |
| 28 Days after 1st Vaccine | 3.6 | 5.2 | 4.5 | 3.3 | 4.9 | 1.9 | 3.7 | 3.7 |
| 42 Days after 1st Vaccine | 2.2 | 2.4 | 2.6 | 1.4 | 1.9 | 1.3 | 2.9 | 2.0 |
| 56 Days after 1st Vaccine | 1.7 | 2.2 | 2.0 | 1.1 | 1.4 | 1.2 | 1.8 | 1.3 |
| 168 Days after 1st Vaccine | 2.7 | 2.7 | 1.8 | 1.3 | 2.7 | 0.9 | 2.7 | 2.7 |
| 252 Days after 1st Vaccine | 1.0 | 3.2 | 1.4 | 3.2 | 1.1 | 1.0 | 1.1 | 1.1 |
| 365 Days after 1st Vaccine | 0.9 | 1.0 | 0.9 | 2.2 | 2.2 | 2.2 | 1.1 | 0.9 |
| Titer | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 40.0 ± 0.0 | 40.0 ± 0.0 | 40.0 ± 0.0 | 40.0 ± 0.0 | 40.0 ± 0.0 | 40.0 ± 0.0 | 40.0 ± 0.0 | 40.0 ± 0.0 | 40.0 ± 0.0 |
| 6 Days | 40.0 ± 0.0 | — | — | — | — | — | 827.8 ± 3859.4 | — | — |
| 14 Days | 928.4 ± 4600.0 | 518.7 ± 1446.0 | 81.0 ± 59.9 | 84.2 ± 78.1 | 2686.8 ± 9365.3 | 780.4 ± 2955.9 | 1847.5 ± 6787.1 | 93.3 ± 78.8 | 1325.2 ± 6386.1 |
| 28 Days | 640.5 ± 2173.9 | 499.8 ± 1420.1 | 136.2 ± 169.8 | 177.7 ± 581.6 | 3887.0 ± 16628.4 | 631.3 ± 1955.2 | 785.6 ± 2134.7 | 113.7 ± 102.0 | 1108.3 ± 5103.2 |
| 42 Days | 4391.0 ± 4567.2 | 2623.7 ± 2216.8 | 1322.6 ± 1198.8 | 1284.8 ± 1434.1 | 6926.8 ± 14487.0 | 3744.3 ± 4066.7 | 4351.9 ± 4553.9 | 1418.2 ± 1414.8 | 2167.2 ± 5160.7 |
| 56 Days | 2594.9 ± 1981.5 | 1818.6 ± 2365.8 | 780.8 ± 771.1 | 716.1 ± 664.9 | 4922.8 ± 11157.3 | 2422.2 ± 2882.7 | 2576.8 ± 2736.1 | 980.8 ± 1015.1 | 1549.5 ± 4334.1 |
| 168 Days | 2889.5 ± 3890.9 | 1756.4 ± 2759.0 | 649.4 ± 791.1 | 1670.2 ± 2774.3 | 3316.2 ± 4137.5 | 1007.5 ± 871.8 | 2968.4 ± 3399.8 | 1261.4 ± 2139.7 | 974.6 ± 1124.6 |
| 252 Days | 10110.8 ± 11107.8 | 3815.0 ± 4058.1 | 2712.6 ± 2898.7 | 4891.0 ± 5258.5 | 4844.8 ± 6960.8 | 6491.6 ± 12406.5 | 7311.4 ± 8802.4 | 7034.7 ± 9548.7 | 5041.1 ± 6443.0 |
| 365 Days | 7250.9 ± 6902.0 | 7184.3 ± 6172.6 | 3934.6 ± 3800.0 | 4408.0 ± 3941.0 | 7070.1 ± 9060.8 | 13175.9 ± 26414.2 | 4949.7 ± 4445.6 | 6287.3 ± 6023.3 | 7174.4 ± 7753.8 |
| Participants | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study | 22 | 13 | 16 | 17 | 15 | 16 | 13 | 16 | 23 |
| Participants | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Throughout the Study | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Participants | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Infusion-related Reactions (Grade ≥2) to REGN10933+REGN10987 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Injection Site Reactions (Grade ≥3) to REGN10933+REGN10987 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Injection Site Reactions (Grade ≥3) to Moderna mRNA-1273 Vaccine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Grade 2 - characterized by an adverse local or general response from exposure and oral intervention indicated Grade 3 - hospitalization indicated and intravenous response required Grade 4 - Life Threatening consequence and urgent intervention indicated Grade 5 - Death
| Participants | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Hypersensitivity Reactions (Grade ≥2) to REGN10933+REGN10987 or Each Dose of Moderna mRNA-1273 Vaccine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| mg/L | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| 0 Days (Pre-dose) | 0.0219 ± 0.114 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 5.12 ± 26.1 | 0 ± 0 | 0 ± 0 |
| 0 Days (End of Infusion) | 145 ± 40.8 | 40.5 ± 16.2 | 26.8 ± 16.9 | 7.84 ± 4.28 | 1.84 ± 0.593 | 140 ± 54.4 | 0.527 ± 0.966 | 0.0765 ± 0.160 |
| 8 Days | — | — | — | — | — | 63.7 ± 11.7 | — | — |
| 14 Days | 46.8 ± 11.3 | 12.7 ± 3.79 | 8.30 ± 3.94 | 2.62 ± 1.44 | 0.536 ± 0.229 | — | 39.4 ± 11.5 | 20.4 ± 7.48 |
| 22 Days | — | — | — | — | — | 39.1 ± 10.9 | — | — |
| 28 Days | 29.5 ± 9.89 | 8.24 ± 3.02 | 5.12 ± 2.28 | 1.76 ± 1.13 | 0.354 ± 0.150 | — | 26.0 ± 8.04 | 14.7 ± 6.25 |
| 36 Days | — | — | — | — | — | 27.7 ± 7.80 | — | — |
| 42 Days | 18.7 ± 7.98 | 5.38 ± 2.40 | 3.35 ± 1.71 | 1.19 ± 0.861 | 0.237 ± 0.114 | — | 17.5 ± 6.30 | 9.77 ± 5.01 |
| 50 Days | — | — | — | — | — | 19.3 ± 5.45 | — | — |
| 56 Days | 13.4 ± 5.87 | 3.51 ± 1.78 | 2.10 ± 1.14 | 0.754 ± 0.569 | 0.131 ± 0.142 | — | 11.6 ± 5.04 | 6.70 ± 3.77 |
| 70 Days | 9.98 ± 6.06 | 2.34 ± 1.33 | 1.42 ± 0.804 | 0.522 ± 0.456 | 0.0105 ± 0.0408 | — | — | — |
| 162 Days | — | — | — | — | — | 1.38 ± 1.00 | — | — |
| 168 Days | — | — | — | — | — | — | 0.891 ± 0.712 | 0.615 ± 0.797 |
| 182 Days | 0.898 ± 1.06 | 0.180 ± 0.212 | 0.137 ± 0.356 | 0.00693 ± 0.0360 | 0 ± 0 | — | — | — |
| mg/L | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| 0 Days (Pre-dose) | 0.0223 ± 0.116 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 6.00 ± 30.6 | 0 ± 0 | 0.00577 ± 0.0341 |
| 0 Days (End of Infusion) | 144 ± 42.5 | 39.6 ± 15.5 | 28.9 ± 26.7 | 8.60 ± 5.10 | 1.91 ± 0.687 | 150 ± 58.0 | 0.580 ± 0.777 | 0.232 ± 0.614 |
| 8 Days | — | — | — | — | — | 61.6 ± 12.0 | — | — |
| 14 Days | 40.0 ± 11.2 | 11.2 ± 3.41 | 7.20 ± 3.09 | 2.33 ± 1.37 | 0.438 ± 0.226 | — | 33.8 ± 9.51 | 18.0 ± 6.15 |
| 22 Days | — | — | — | — | — | 35.0 ± 10.5 | — | — |
| 28 Days | 23.8 ± 9.92 | 6.87 ± 2.84 | 4.19 ± 1.95 | 1.46 ± 0.968 | 0.263 ± 0.189 | — | 21.0 ± 6.95 | 12.1 ± 5.92 |
| 36 Days | — | — | — | — | — | 22.2 ± 6.56 | — | — |
| 42 Days | 13.7 ± 6.86 | 4.00 ± 2.02 | 2.54 ± 1.35 | 0.868 ± 0.641 | 0.138 ± 0.147 | — | 13.3 ± 6.11 | 7.71 ± 4.42 |
| 50 Days | — | — | — | — | — | 14.5 ± 4.09 | — | — |
| 56 Days | 9.23 ± 4.97 | 2.51 ± 1.48 | 1.55 ± 0.903 | 0.507 ± 0.453 | 0.0776 ± 0.138 | — | 8.02 ± 3.99 | 4.86 ± 3.07 |
| 70 Days | 6.51 ± 4.53 | 1.57 ± 1.04 | 0.993 ± 0.630 | 0.306 ± 0.344 | 0.0115 ± 0.0444 | — | — | — |
| 162 Days | — | — | — | — | — | 0.566 ± 0.560 | — | — |
| 168 Days | — | — | — | — | — | — | 0.347 ± 0.378 | 0.251 ± 0.465 |
| 182 Days | 0.400 ± 0.617 | 0.0401 ± 0.124 | 0.0408 ± 0.179 | 0 ± 0 | 0 ± 0 | — | — | — |
| Percent of Participants | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Negative | 48.1 | 55.6 | 44.4 | 46.7 | 56.7 | 56.5 | 55.9 | 57.1 |
| Pre-Existing Immunoreactivity | 7.4 | 0 | 3.7 | 3.3 | 3.3 | 8.7 | 0 | 5.7 |
| Treatment-Boosted Response | 0 | 0 | 0 | 3.3 | 0 | 0 | 2.9 | 0 |
| Percent of Participants | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| Negative | 66.7 | 59.3 | 44.4 | 30.0 | 36.7 | 91.3 | 70.6 | 62.9 |
| Pre-Existing Immunoreactivity | 0 | 3.7 | 3.7 | 6.7 | 0 | 0 | 0 | 0 |
| Treatment-Boosted Response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| NAb Negative | 16 | 12 | 16 | 17 | 20 | 15 | 24 | 22 |
| NAb Positive | 11 | 6 | 11 | 13 | 10 | 8 | 10 | 13 |
| Participants | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC |
|---|---|---|---|---|---|---|---|---|
| NAb Negative | 27 | 25 | 26 | 22 | 23 | 21 | 32 | 32 |
| Nab Positive | 0 | 2 | 1 | 8 | 7 | 2 | 2 | 3 |
Collected over Up to 401 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vaccine Only Total All | 0/48 (0%) | 2/48 (4.2%) | 11/48 (22.9%) |
| REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | 0/28 (0%) | 0/28 (0%) | 13/28 (46.4%) |
| REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | 0/29 (0%) | 0/29 (0%) | 9/29 (31%) |
| REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | 0/28 (0%) | 0/28 (0%) | 14/28 (50%) |
| REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | 0/35 (0%) | 1/35 (2.9%) | 15/35 (42.9%) |
| REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC | 0/35 (0%) | 0/35 (0%) | 23/35 (65.7%) |
| REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | 0/33 (0%) | 0/33 (0%) | 12/33 (36.4%) |
| REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | 0/31 (0%) | 0/31 (0%) | 14/31 (45.2%) |
| REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | 1/26 (3.8%) | 2/26 (7.7%) | 9/26 (34.6%) |
| Event | Vaccine Only Total All | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV |
|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/48 | 0/28 | 0/29 | 0/28 | 0/35 | 0/35 | 0/33 | 0/31 | 1/26 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/48 | 0/28 | 0/29 | 0/28 | 0/35 | 0/35 | 0/33 | 0/31 | 1/26 |
| GastritisGastrointestinal disorders | 0/48 | 0/28 | 0/29 | 0/28 | 1/35 | 0/35 | 0/33 | 0/31 | 0/26 |
| CholelithiasisHepatobiliary disorders | 1/48 | 0/28 | 0/29 | 0/28 | 0/35 | 0/35 | 0/33 | 0/31 | 0/26 |
| Diabetic foot infectionInfections and infestations | 1/48 | 0/28 | 0/29 | 0/28 | 0/35 | 0/35 | 0/33 | 0/31 | 0/26 |
| Event | Vaccine Only Total All | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV |
|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 2/48 | 2/28 | 1/29 | 1/28 | 7/35 | 12/35 | 1/33 | 1/31 | 5/26 |
| Asymptomatic COVID-19Infections and infestations | 3/48 | 2/28 | 4/29 | 9/28 | 6/35 | 7/35 | 4/33 | 4/31 | 1/26 |
| COVID-19Infections and infestations | 5/48 | 7/28 | 3/29 | 3/28 | 7/35 | 6/35 | 0/33 | 6/31 | 3/26 |
| HeadacheNervous system disorders | 3/48 | 1/28 | 1/29 | 1/28 | 2/35 | 4/35 | 3/33 | 3/31 | 1/26 |
| PyrexiaGeneral disorders | 0/48 | 1/28 | 0/29 | 0/28 | 0/35 | 3/35 | 2/33 | 1/31 | 2/26 |
| Upper respiratory tract infectionInfections and infestations | 0/48 | 2/28 | 1/29 | 0/28 | 1/35 | 0/35 | 0/33 | 0/31 | 0/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/48 | 2/28 | 1/29 | 0/28 | 0/35 | 0/35 | 1/33 | 2/31 | 0/26 |
| CellulitisInfections and infestations | 0/48 | 0/28 | 0/29 | 0/28 | 1/35 | 0/35 | 0/33 | 2/31 | 0/26 |
| ChillsGeneral disorders | 0/48 | 1/28 | 0/29 | 0/28 | 0/35 | 1/35 | 2/33 | 0/31 | 1/26 |
| HypertensionVascular disorders | 1/48 | 1/28 | 1/29 | 0/28 | 0/35 | 1/35 | 2/33 | 0/31 | 1/26 |
The safety analysis set (SAF) includes all randomized subjects who have been vaccinated with at least one dose or received any study drug
| Age, Customized(years) | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 40.2 ± 12.17 | 41.8 ± 13.98 | 39.3 ± 12.76 | 39.7 ± 13.50 | 41.6 ± 12.73 | 41.1 ± 11.23 | 39.8 ± 13.76 | 43.8 ± 12.99 | 46.3 ± 11.53 | 41.6 ± 12.70 |
| Sex: Female, Male(Participants) | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 28 | 13 | 9 | 13 | 17 | 16 | 14 | 14 | 19 | 143 |
| Male | 20 | 15 | 20 | 15 | 16 | 15 | 12 | 21 | 16 | 150 |
| Ethnicity (NIH/OMB)(Participants) | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 16 | 9 | 12 | 9 | 16 | 19 | 17 | 11 | 12 | 121 |
| Not Hispanic or Latino | 31 | 19 | 17 | 19 | 17 | 12 | 9 | 24 | 23 | 171 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Vaccine Only | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV | REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC | REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 3 |
| Asian | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 16 | 10 | 7 | 9 | 9 | 7 | 7 | 10 | 7 | 82 |
| White | 32 | 18 | 22 | 18 | 23 | 21 | 19 | 24 | 27 | 204 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Apr 2021 to primary completion in Nov 2022, 18 months.
Results were first posted in Aug 2024, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.